J B Adizie1, A Khakwani2, P Beckett3, N Navani3, D West3, I Woolhouse4, S V Harden3. 1. University Hospitals Birmingham, Birmingham, UK. Electronic address: j.adizie@nhs.net. 2. Department of Epidemiology and Public Health, University of Nottingham, Nottingham, UK. 3. Care Quality Improvement Department, Royal College of Physicians, London, UK. 4. University Hospitals Birmingham, Birmingham, UK.
Abstract
AIMS: We present the first analysis of the management and outcomes of stage III non-small cell lung cancer (NSCLC) conducted in England using National Lung Cancer Audit data. MATERIALS AND METHODS: Patients diagnosed with stage III NSCLC in 2016 were identified. Linked datasets (including Hospital Episode Statistics, the National Radiotherapy Dataset, the Systemic Anti-Cancer Dataset, pathology reports and death certificate data) were used to categorise the treatment received. Kaplan-Meier survival curves were obtained, with survival defined from the date of diagnosis to the date of death. RESULTS: In total, 6276 cases of stage III NSCLC were analysed: 3827 stage IIIA and 2449 stage IIIB; 1047 (17%) patients were treated with radical radiotherapy with 676 (11%) of these also receiving chemotherapy. Twenty per cent of patients with stage IIIA disease underwent surgery, with half of these also receiving chemotherapy, predominantly delivered in the adjuvant setting. Of note, 2148 (34%) patients received palliative-intent treatment and 2265 (36%) received no active anti-cancer treatment. The 1-year survival was 32.9% (37.4% for stage IIIA), with the highest survival seen for those patients receiving chemotherapy and surgery. CONCLUSIONS: We highlight important gaps in the optimal care of patients with stage III NSCLC in England. Multimodality treatment with either surgery or radical radiotherapy combined with chemotherapy was delivered to less than one-fifth of patients, even though these regimens are considered optimal. Timely access to specialist resources and staff, the practice of effective shared decision making and challenging preconceptions have the potential to optimise management.
AIMS: We present the first analysis of the management and outcomes of stage III non-small cell lung cancer (NSCLC) conducted in England using National Lung Cancer Audit data. MATERIALS AND METHODS:Patients diagnosed with stage III NSCLC in 2016 were identified. Linked datasets (including Hospital Episode Statistics, the National Radiotherapy Dataset, the Systemic Anti-Cancer Dataset, pathology reports and death certificate data) were used to categorise the treatment received. Kaplan-Meier survival curves were obtained, with survival defined from the date of diagnosis to the date of death. RESULTS: In total, 6276 cases of stage III NSCLC were analysed: 3827 stage IIIA and 2449 stage IIIB; 1047 (17%) patients were treated with radical radiotherapy with 676 (11%) of these also receiving chemotherapy. Twenty per cent of patients with stage IIIA disease underwent surgery, with half of these also receiving chemotherapy, predominantly delivered in the adjuvant setting. Of note, 2148 (34%) patients received palliative-intent treatment and 2265 (36%) received no active anti-cancer treatment. The 1-year survival was 32.9% (37.4% for stage IIIA), with the highest survival seen for those patients receiving chemotherapy and surgery. CONCLUSIONS: We highlight important gaps in the optimal care of patients with stage III NSCLC in England. Multimodality treatment with either surgery or radical radiotherapy combined with chemotherapy was delivered to less than one-fifth of patients, even though these regimens are considered optimal. Timely access to specialist resources and staff, the practice of effective shared decision making and challenging preconceptions have the potential to optimise management.
Authors: Ana Casal-Mouriño; Alberto Ruano-Ravina; María Lorenzo-González; Ángeles Rodríguez-Martínez; Alexandra Giraldo-Osorio; Leonor Varela-Lema; Tara Pereiro-Brea; Juan Miguel Barros-Dios; Luis Valdés-Cuadrado; Mónica Pérez-Ríos Journal: Transl Lung Cancer Res Date: 2021-01
Authors: K Haslett; P Koh; A Hudson; W D Ryder; S Falk; D Mullan; B Taylor; R Califano; F Blackhall; C Faivre-Finn Journal: Clin Transl Radiat Oncol Date: 2021-02-25
Authors: Kate Haslett; Neil Bayman; Kevin Franks; Nicki Groom; Susan V Harden; Catherine Harris; Gerard Hanna; Stephen Harrow; Matthew Hatton; Paula McCloskey; Fiona McDonald; W David Ryder; Corinne Faivre-Finn Journal: Int J Radiat Oncol Biol Phys Date: 2020-11-21 Impact factor: 7.038
Authors: Markus Glatzer; Pawel Leskow; Francesca Caparrotti; Olgun Elicin; Markus Furrer; Franco Gambazzi; André Dutly; Hans Gelpke; Matthias Guckenberger; Jürg Heuberger; Rolf Inderbitzi; Stefano Cafarotti; Wolfram Karenovics; Peter Kestenholz; Gregor Jan Kocher; Peter Kraxner; Thorsten Krueger; Francesco Martucci; Christoph Oehler; Mahmut Ozsahin; Alexandros Papachristofilou; Dirk Wagnetz; Kathrin Zaugg; Daniel Zwahlen; Isabelle Opitz; Paul Martin Putora Journal: Transl Lung Cancer Res Date: 2021-04
Authors: Meredith A Ray; Nicholas R Faris; Carrie Fehnel; Anna Derrick; Matthew P Smeltzer; Meghan B Meadows-Taylor; Folabi Ariganjoye; Alicia Pacheco; Robert Optican; Keith Tonkin; Jeffrey Wright; Roy Fox; Thomas Callahan; Edward T Robbins; William Walsh; Philip Lammers; Shailesh Satpute; Raymond U Osarogiagbon Journal: JTO Clin Res Rep Date: 2021-07-03
Authors: Merle I Ronden; Idris Bahce; Niels J M Claessens; Nicole Barlo; Max R Dahele; Johannes M A Daniels; Caroline Tissing-Tan; Edo Hekma; Sayed M S Hashemi; Antoinet van der Wel; Femke O B Spoelstra; Wilko F A R Verbakel; Marian A Tiemessen; Marjolein van Laren; Annemarie Becker; Svitlana Tarasevych; Cornelis J A Haasbeek; Karen Maassen van den Brink; Chris Dickhoff; Suresh Senan Journal: JTO Clin Res Rep Date: 2021-06-06
Authors: Sally Taylor; Janelle Yorke; Selina Tsim; Neal Navani; David Baldwin; Ian Woolhouse; John Edwards; Seamus Grundy; Jonathan Robson; Sarah Rhodes; Fabio Gomes; Fiona Blackhall; Corinne Faivre-Finn; Matthew Evison Journal: BMJ Open Respir Res Date: 2021-07
Authors: Gerard M Walls; Jamie B Oughton; Anthony J Chalmers; Sarah Brown; Fiona Collinson; Martin D Forster; Kevin N Franks; Alexandra Gilbert; Gerard G Hanna; Nicola Hannaway; Stephen Harrow; Tom Haswell; Crispin T Hiley; Samantha Hinsley; Matthew Krebs; Geraldine Murden; Rachel Phillip; Anderson J Ryan; Ahmed Salem; David Sebag-Montefoire; Paul Shaw; Chris J Twelves; Katrina Walker; Robin J Young; Corinne Faivre-Finn; Alastair Greystoke Journal: Clin Transl Radiat Oncol Date: 2020-09-22